StonvexLoading…
StonvexStonvexStonvexCore line items from IBRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $113.29M | $14.74M | $622.00K | $240.00K |
Operating Income | $-256.03M | $-344.18M | $-362.25M | $-351.30M |
Net Income | $-351.40M | $-413.56M | $-583.20M | $-416.57M |
EPS (Diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 |
Total Assets | $501.90M | $382.93M | $504.45M | $362.36M |
Total Liabilities | $1.00B | $871.06M | $1.09B | $812.18M |
Cash & Equivalents | $88.33M | $143.43M | $265.45M | $104.64M |
Free Cash Flow OCF − CapEx | $-308.78M | $-398.12M | $-397.34M | $-415.67M |
Shares Outstanding | 1.01B | 852.90M | 670.87M | 421.57M |